soul trial oral semaglutide cardiovascular outcomes 2025 benefit study in High-Risk Type 2 Diabetes: Confirmed in the Trial Scorecard: SOUL – Oral Semaglutide in High-Risk Type – Study Finds Oral Semaglutide Vastly

*Correspondence: Fernando Lizcano, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Researchers using other peptide-based treatments alongside the PTD-DBM protocol should be aware that potential interactions have not been characterized

Most importantly, injectable formats are prescribed and administered under medical supervision, which helps ensure proper dosing, safety, and program suitability for each individual

10.2217/bmm-2017-0109 9

Smits, Mark M, and Danil H Van Raalte

These injections promise rapid weight loss and are often claimed to increase metabolism and boost energy levels